AlloVir

Quick facts

Phase 1 pipeline

• Multivirus Specific T cells
• Multivirus-specific T cells Dose Level 1
• Multivirus-specific T cells Dose Level 2
• Multivirus-specific T cells Dose Level 3
• Viralym-C

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• AlloVir portfolio CI brief
• AlloVir pipeline updates RSS